Errors in the Results and Table

In the Research Letter titled “Pediatric Exclusivity for Cancer Drugs,” published online on November 11, 2024, there were errors in the Results section and Table. The standard deviation for the cost of investment per trial should be 11 instead of 4, and the standard deviation for the cost of investment per exclusivity should be 12 instead of 4. The revenue from exclusivity should be $1237 million instead of $1236 million. In the sensitivity analyses, the revenue range should have appeared as $228 million to $400 million instead of $259 million to $454 million. In the estimated revenue column in the Table, 416 should be 389, 48 should be 42, and 875 should be 741. This article has been corrected.